Viela Bio Inc.

Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global

Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more

Plus new name, COVID-19 mAb for Adagio and updates from Horizon, Acadia, Chiesi and more

Plus new CMO, SVP of clinical development at Alumis, and updates from Vertex, Third Rock, AiCuris and more

Plus restructuring at Invitae brings new CEO, and updates from Codexis, Compass, Tectonic and more

Plus Legend hires Zymeworks alum Fang to lead research, early development and updates from Freenome, Urovant, Tessa, eGenesis

Plus: Biogen readies confirmatory trial of Aduhelm, Senate passes ALS bill and updates from NIH, Regeneron, Horizon-Alpine and more

Plus: Sage, Gossamer Bio, Nimbus, Inventiva, Selecta and more

Emerging Company Profile: After Viela exit, Yao launches company bringing China assets to the West

Months after broadening its pipeline via the $3 billion-plus takeout of Viela, Horizon is adding to its gout franchise through a smaller deal with Arrowhead for a preclinical siRNA therapeutic.